Cargando…

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

Renal cell carcinoma (RCC) comprises a highly heterogeneous group of kidney tumours built upon distinct genetic- and epigenetic-driven mechanisms and molecular pathways. Therefore, responsiveness to treatment is considerably variable across patients, adding an extra layer of complexity to the alread...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontes-Sousa, Mário, Magalhães, Helena, Oliveira, Alicia, Carneiro, Filipa, dos Reis, Filipa Palma, Madeira, Pedro Silvestre, Meireles, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756748/ https://www.ncbi.nlm.nih.gov/pubmed/35025061 http://dx.doi.org/10.1007/s12325-021-02007-y

Ejemplares similares

Is imatinib still the best choice as first-line oral TKI
por: Bansal, Shweta
Publicado: (2014)

Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review
por: Sardinha, Mariana, et al.
Publicado: (2023)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Is there still a place for thrombectomy?
por: Dąbrowski, Maciej, et al.
Publicado: (2016)

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
por: Decraecker, Marie, et al.
Publicado: (2021)

Arthroscopic remplissage: Is it still an option?
por: Morsy, Mohamed G.
Publicado: (2017)

Therapeutic Options in Refractory Evans Syndrome: A Case Report
por: Jancar, Nina, et al.
Publicado: (2022)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Placing the Tracker inside CMS (still wrapped)
por: Hoch, Michael
Publicado: (2007)

Considerations of systemic treatment for matrix-producing carcinoma with curative intent
por: de Paula, Bruno, et al.
Publicado: (2022)

Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?
por: Desjardins, Clément, et al.
Publicado: (2023)

Halothane: Is there still any place for using the gas as an anesthetic?
por: Dabbagh, Ali, et al.
Publicado: (2011)

Is there still a place for vasopressors in the treatment of cardiac arrest?
por: Sandroni, Claudio, et al.
Publicado: (2012)

Is there still a place for transcranial Doppler in patients with IABP?
por: Caldas, Juliana R., et al.
Publicado: (2020)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Is there still a place for methotrexate in severe psoriatic arthritis?
por: Felten, Renaud, et al.
Publicado: (2022)

Is There Still a Place for Percutaneous Nephrolithotomy in Current Times?
por: De Lorenzis, Elisa, et al.
Publicado: (2022)

Is There Still a Place to Study Race in the Nephrology Space?
por: Rifkin, Brian
Publicado: (2023)

Is There Still a Place for Forceps Delivery in Modern Obstetrics?
por: Zając, Katarzyna, et al.
Publicado: (2023)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
por: Palma dos Reis, Ana Filipa, et al.
Publicado: (2022)

Hypertriglyceridemic Pancreatitis: Is Insulin Monotherapy A Feasible Therapeutic Option?
por: Inayat, Faisal, et al.
Publicado: (2018)

Percutaneous balloon mitral valvuloplasty: is there still a place for it in the Netherlands?
por: den Heijer, P.
Publicado: (2019)

XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?
por: Del Giacomo, Paola, et al.
Publicado: (2022)

Is There Still a Place for Reconstructive Surgery in Distal Tubal Disease?
por: Obrzut, Bogdan, et al.
Publicado: (2022)

Reliability and Efficacy of the Epworth Sleepiness Scale: Is There Still a Place for It?
por: Scharf, Matthew T
Publicado: (2022)

COVID 19 convalescent plasma: Is there still a place for CCP?
por: Moog, Rainer
Publicado: (2023)

Is There Still a Place for Surgery in Patients with PCOS? A Review
por: Della Corte, Luigi, et al.
Publicado: (2023)

Pulmonary Artery Banding is Still a Valuable Option
por: Durandy, Yves
Publicado: (2013)

Adult colonic intussusception: Surgery still the best option
por: Dungerwalla, M, et al.
Publicado: (2012)

In the era of broad spectrum antibiotics, is ampicillin still an option?
por: Popescu, Cristina, et al.
Publicado: (2013)

Bone biopsy in chronic kidney disease: still an option?
por: Drueke, Tilman B.
Publicado: (2020)

Is Vaginal Breech Delivery Still a Safe Option?
por: Pulido Valente, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ur0lujb29cujho44sa8im1ngnj